港股異動 | 復星醫藥跌5% 子公司終止萬格列淨片藥品臨牀試驗及後續開發
格隆匯12月29日丨港股復星醫藥(2196.HK)盤中跌5.71%,報32.2港元;A股復興醫藥(600196.SH)盤中跌1.85%,報48.8元人民幣,總市值1251億元人民幣。復星醫藥12月28日發佈公吿,基於後續開發投入和市場價值等因素綜合評估,控股子公司江蘇萬邦決定終止萬格列淨片藥品臨牀試驗及後續開發。該新藥為SGLT-2抑制劑,主要用於II型糖尿病的治療。此外,公司控股子公司寧波復瀛與國藥中金簽訂合夥協議,擬共同設立目標基金,並專項用於對宸汐健康的投資,目標基金計劃募資1111萬元。宸汐健康系今年11月新設公司,業務範圍包括提供政策保險服務、商業健康險服務等。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.